Immunotherapy in prostate cancer: current state and future perspectives

Shivani Handa, Bandhul Hans, Shokhi Goel, Hafis O. Bashorun, Zach Dovey, Ashutosh Tewari

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Metastatic castrate resistant prostate cancer (PCa) remains an incurable entity. In the era of immunotherapy, the complex PCa microenvironment poses a unique challenge to the successful application of this class of agents. However, in the last decade, a tremendous effort has been made to explore this field of therapeutics. In this review, the physiology of the cancer immunity cycle is highlighted in the context of the prostate tumor microenvironment, and the current evidence for use of various classes of immunotherapy agents including vaccines (dendritic cell based, viral vector based and DNA/mRNA based), immune checkpoint inhibitors, Chimeric antigen receptor T cell therapy, antibody-mediated radioimmunotherapy, antibody drug conjugates, and bispecific antibodies, is consolidated. Finally, the future directions for combinatorial approaches to combat PCa are discussed.

Original languageEnglish
JournalTherapeutic Advances in Urology
StatePublished - 2020


  • CAR-T cell
  • Prostate cancer
  • Sipuleucel-T
  • adoptive cell therapy
  • cancer vaccines
  • cancer-immunity cycle
  • immune checkpoint inhibitor
  • immunotherapy
  • metastatic castration resistant prostate cancer
  • radioimmunotherapy


Dive into the research topics of 'Immunotherapy in prostate cancer: current state and future perspectives'. Together they form a unique fingerprint.

Cite this